David J. Sher, MD, MPH

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Predictors of IMRT and Conformal Radiotherapy Use in Head and Neck Squamous Cell Carcinoma: A SEER-Medicare Analysis.
   Sher DJ, Neville BA, Chen AB, Schrag D.
   Int J Radiat Oncol Biol Phys.
   2011 May 17
   
2. Clinical Utility of 4D FDG-PET/CT Scans in Radiation Treatment Planning.
   Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB.
   Int J Radiat Oncol Biol Phys.
   2011 Mar 4
   
3. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: A decision analysis.
   Parikh R, Sher DJ.
   Cancer.
   2011 Jun 30
   doi: 10.1002/cncr.26272
   
4. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation.
   Chen AB, Neville BA, Sher DJ, Chen K, Schrag D.
   J Clin Oncol.
   2011 Jun 10
   29(17):2305-11
   
5. Effect of respiratory trace shape on optimal treatment margin.
   Winey B, Wagar M, Ebe K, Popple R, Lingos T, Sher D, Court L.
   Med Phys
   2011 Jun
   38(6):3125-9.
   
6. Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
   Sher DJ, Wee JO, Punglia RS.
   Int J Radiat Oncol Biol Phys.
   2011 Feb 10
   
7. Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX 324.
   Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM.
   Int J Radiat Oncol Biol Phys.
   2011 Feb 10
   
8. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.
   Sher DJ, Balboni TA, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB.
   Int J Radiat Oncol Biol Phys.
   2011 Aug 1
   80(5):1405-11
   
9. Treatment of Oral Cavity Squamous Cell Carcinoma with Adjuvant or Definitive Intensity-Modulated Radiation Therapy.
   Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB.
   Int J Radiat Oncol Biol Phys.
   2011 Apr 29
   
10. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
    Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, Choueiri TK.
    J Clin Oncol.
    2010 Sep 1
    28(25):e433-5
    
11. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy.
    Goguen LA, Chapuy CI, Sher DJ, Israel DA, Blinder RA, Norris CM, Tishler RB, Haddad RI, Annino DJ.
    Otolaryngol Head Neck Surg.
    2010 Sep
    143(3):367-74.
    
12. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB.
    Cancer.
    2010 Oct 15
    116(20):4761-8.
    
13. Cost-effectiveness studies in radiation therapy.
    Sher DJ.
    Expert Rev Pharmacoecon Outcomes Res.
    2010 Oct
    10(5):567-82
    
14. Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy.
    Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB.
    Int J Radiat Oncol Biol Phys.
    2010 Nov 12
    
15. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.
    Sher DJ, Tishler RB, Annino D, Punglia RS.
    Ann Oncol.
    2010 May
    21(5):1072-7
    
16. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
    Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK.
    Ann Oncol.
    2009 Nov
    20(11):1848-53
    
17. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
    Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS.
    Int J Radiat Oncol Biol Phys.
    2009 Jun 1
    74(2):440-6
    
18. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK.
    Urology.
    2009 Feb
    73(2):356-61; discussion 361-2
    
19. Relationship between serum adiponectin and prostate cancer grade.
    Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C.
    Prostate.
    2008 Oct 1
    68(14):1592-8.
    
20. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.
    J Neurooncol.
    2008 May
    88(1):43-50
    
21. Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis.
    Sher DJ, Wittenberg E, Taghian AG, Bellon JR, Punglia RS.
    Int J Radiat Oncol Biol Phys.
    2008 Feb 1
    70(2):469-76
    
22. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer
    Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W Jr
    Int J Radiat Oncol Biol Phys
    2008 Feb 1
    70(2):477-84
    

• To watch a brief video of David J. Sher, MD, MPH, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• I work specifically in the thoracic lung cancer group, as well as the head and neck group. And so I work with the entire teams — the medical oncologists, and the surgeons, and both of those groups as a team — to deliver radiotherapy.

  The more coordination you have with your surgical colleagues, medical oncologists, a tight nursing staff who works very closely with the physicians, outcomes are better. Decisions are made around a table, where you’re looking at all of the information at the same time, with all of the different disciplines, saying [motioning with his hands as if he is addressing a team of doctors in a meeting], “I can do this.” “We should do this.” “This is the best for the patient.”

  The field, in general, has moved in many different directions — all of which are moving to better outcomes, better quality of life after treatment. Just big picture —you have more integration of chemotherapy with the radiation treatment. That has improved cure rates and it’s improved long-term survival — obviously [that’s] very important. From a radiation standpoint, our tools are much more precise. They’re able to deliver much more treatment actually to the disease itself, less radiation to normal tissues. And this, depending on the disease site, can dramatically change the outcomes, or simply the experience of the quality of life following therapy.